Literature DB >> 1978634

Substantia nigra: a site of action of muscle relaxant drugs.

L Turski1, T Klockgether, M Schwarz, W A Turski, K H Sontag.   

Abstract

Sites of action of centrally active muscle relaxant drugs are not well defined. Clinical experience with such drugs suggests that the spinal cord may be one of the important regions from which pathologically increased muscle tone may be relieved. Supraspinal centers that may also be involved in the expression of muscle relaxant action have not yet been defined. We report here that microinjections of therapeutically relevant muscle relaxants into the midbrain tegmentum of genetically spastic rats decrease muscle tone. The substantia nigra is the region from which midazolam, baclofen, and tizanidine (drugs used clinically in the treatment of spasticity), or gamma-vinyl-GABA, (-)-2-amino-7-phosphonoheptanoate, and [D-pro2-D-phe7-D-trp9]-substance P (experimental drugs active in animal models of spasticity), reduce muscle tone in genetically spastic rats and Hoffmann reflexes in normal rats. The effects of muscle relaxant drugs are topographically restricted to the substantia nigra pars reticulata and are receptor specific. These observations disclose a previously unknown function of the substantia nigra in mediating muscle relaxation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1978634     DOI: 10.1002/ana.410280307

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  5 in total

1.  Differential sensitivity to the motor and hypothermic effects of the GABA B receptor agonist baclofen in various mouse strains.

Authors:  Laura H Jacobson; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2005-01-25       Impact factor: 4.530

2.  Alprazolam dependence prevented by substituting with the beta-carboline abecarnil.

Authors:  G Pinna; R Galici; H H Schneider; D N Stephens; L Turski
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

Review 3.  Therapeutic potential of cannabinoids in CNS disease.

Authors:  J Ludovic Croxford
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

5.  [Respiratory failure due to delta-9-tetrahydrocannabinol in a tetraplegic patient].

Authors:  M Neuburger; M Schley; M Schmelz; G Schuepfer; C Konrad
Journal:  Schmerz       Date:  2006-11       Impact factor: 1.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.